Efficacy and Safety of Dabigatran Compared to Warfarin for 6 Month Treatment of Acute Symptomatic Venous Thromboembolism
- Conditions
- Thromboembolism
- Interventions
- Registration Number
- NCT00291330
- Lead Sponsor
- Boehringer Ingelheim
- Brief Summary
The purpose of this trial is to determine the comparative safety and efficacy of dabigatran etexilate 150 mg bid administered orally and warfarin as needed (pro re nata - prn) to maintain an International Normalised Ratio (INR) of 2.0-3.0 for 6 month treatment of acute symptomatic venous thromboembolism (VTE), following initial treatment (5-10 days) with a parenteral anticoagulant approved for this indication. This trial aims to demonstrate non-inferiority of dabigatran compared with warfarin in patients with acute symptomatic VTE. After achieving non-inferiority, this trial also aims to establish superiority (by means of hierarchical tests) of dabigatran over warfarin.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 2564
Not provided
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description dabigatran etexilate 150 mg dabigatran etexilate 150 mg twice daily warfarin (INR 2-3) warfarin (INR 2-3) prn to maintain INR (2-3)
- Primary Outcome Measures
Name Time Method Number of Participants With Recurrent Symptomatic Venous Thromboembolism (VTE) and Deaths Related to VTE For statistical analysis 1: from randomisation to end of post treatment period (ptp), planned to be up to day 224. For statistical analysis 2: from randomisation to 6 months (up to day 180) All suspected recurrent VTEs and all deaths and bleeding events were evaluated by an independent central adjudication committee, and all analyses are based on the events that were centrally confirmed by this committee.
- Secondary Outcome Measures
Name Time Method Number of Participants With Recurrent Symptomatic VTE and All Deaths For statistical analysis 1: from randomisation to 6 months (up to day 180) For statistical analysis 2: from randomisation to end of ptp, planned to be up to day 224. VTE or any death which occured from randomisation to end of post treatment period.
All suspected recurrent VTEs and all deaths and bleeding events were evaluated by an independent central adjudication committee, and all analyses are based on the events that were centrally confirmed by this committee.Number of Participants With Recurrent Symptomatic DVT For statistical analysis 1: from randomisation to 6 months (up to day 180) For statistical analysis 2: from randomisation to end of ptp, planned to be up to day 224. Symptomatic DVT which occured from randomisation to end of post treatment period.
All suspected recurrent VTEs and all deaths and bleeding events were evaluated by an independent central adjudication committee, and all analyses are based on the events that were centrally confirmed by this committee.Number of Participants Who Died (Any Cause) For statistical analysis 1: from randomisation to 6 months (up to day 180) For statistical analysis 2: from randomisation to end of ptp, planned to be up to day 224. Any deaths which occured from randomisation to end of post treatment period. All suspected recurrent VTEs and all deaths and bleeding events were evaluated by an independent central adjudication committee, and all analyses are based on the events that were centrally confirmed by this committee.
Laboratory Analyses From first intake of study drug to last intake of study drug + 6 days washout (washout time can be reduced until 0 day if the patient takes an other anti-coagulant therapy on and after last intake of active study drug) Frequency of patients with possible clinically significant abnormalities.
Number of Participants With Recurrent Symptomatic Non-fatal PE For statistical analysis 1: from randomisation to 6 months (up to day 180) For statistical analysis 2: from randomisation to end of ptp, planned to be up to day 224. Symptomatic non-fatal PE which occured from randomisation to end of post treatment period.
All suspected recurrent VTEs and all deaths and bleeding events were evaluated by an independent central adjudication committee, and all analyses are based on the events that were centrally confirmed by this committee.Number of Participants With Bleeding Events From first intake of study drug to last intake of study drug + 6 days washout (washout time can be reduced until 0 day if the patient takes an other anti-coagulant therapy on and after last intake of active study drug) Major bleeding events (MBE) were defined as
* Fatal bleeding
* Symptomatic bleeding in a critical area or organ
* Bleeding causing a fall in haemoglobin level of 20 g/L (1.24 mmol/L) or more, or leading to transfusion of 2 or more units of whole blood or red cells
Clinically-relevant bleeding events (CRBE) was defined as
* spontaneous skin hematoma \>=25 cm²
* spontaneous nose bleed \>5 min
* macroscopic hematuria spontaneous or \>24 hours if associated with an intervention
* spontaneous rectal bleeding (more than spotting on toilet paper)
* gingival bleeding \>5 min
* leading to hospitalisation and / or requiring surgical treatment
* leading to a transfusion of \<2 units of whole blood or red cells
* any other bleeding event considered clinically relevant by the investigator
Any bleeding events were defined as major, clinically-relevant and nuisance bleeding events. Nuisance bleeding events were defined as all other bleeding events that did not fulfil the criteria from above.Number of Participants Who Died Due to VTE For statistical analysis 1: from randomisation to 6 months (up to day 180) For statistical analysis 2: from randomisation to end of ptp, planned to be up to day 224. VTE - related deaths which occured from randomisation to end of post treatment period.
All suspected recurrent VTEs and all deaths and bleeding events were evaluated by an independent central adjudication committee, and all analyses are based on the events that were centrally confirmed by this committee.Number of Participants With Acute Coronary Syndrome (ACS) From first intake of study drug to end of study conduct Any ACS occurring during the conduct of the study (centrally adjudicated as definite).
Counts of patients having a centrally adjudicated definite ACS during intake of active study drug, after stopping active study drug and before or without intake of active study drug, according to treatment group.
All suspected recurrent VTEs and all deaths and bleeding events were evaluated by an independent central adjudication committee, and all analyses are based on the events that were centrally confirmed by this committee.
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
Trial Locations
- Locations (250)
1160.53.01033 Boehringer Ingelheim Investigational Site
🇺🇸Sarasota, Florida, United States
1160.53.01046 Boehringer Ingelheim Investigational Site
🇺🇸Sarasota, Florida, United States
1160.53.01010 Boehringer Ingelheim Investigational Site
🇺🇸Marietta, Georgia, United States
1160.53.01027 Boehringer Ingelheim Investigational Site
🇺🇸Chapel Hill, North Carolina, United States
1160.53.01031 Boehringer Ingelheim Investigational Site
🇺🇸Lebanon, New Hampshire, United States
1160.53.01009 Boehringer Ingelheim Investigational Site
🇺🇸St. Louis Park, Minnesota, United States
1160.53.01044 Boehringer Ingelheim Investigational Site
🇺🇸Clearwater, Florida, United States
1160.53.01039 Boehringer Ingelheim Investigational Site
🇺🇸Winston-Salem, North Carolina, United States
1160.53.01013 Boehringer Ingelheim Investigational Site
🇺🇸Toledo, Ohio, United States
1160.53.91012 Boehringer Ingelheim Investigational Site
🇮🇳Chennai, India
1160.53.01014 Boehringer Ingelheim Investigational Site
🇺🇸Baltimore, Maryland, United States
1160.53.43003 Boehringer Ingelheim Investigational Site
🇦🇹Innsbruck, Austria
1160.53.43002 Boehringer Ingelheim Investigational Site
🇦🇹Wien, Austria
1160.53.32002 Boehringer Ingelheim Investigational Site
🇧🇪Bruxelles, Belgium
1160.53.54007 Boehringer Ingelheim Investigational Site
🇦🇷Capital Federal, Argentina
1160.53.55016 Boehringer Ingelheim Investigational Site
🇧🇷Rio de Janeiro - RJ, Brazil
1160.53.55004 Boehringer Ingelheim Investigational Site
🇧🇷Santo André, Brazil
1160.53.01035 Boehringer Ingelheim Investigational Site
🇺🇸Mobile, Alabama, United States
1160.53.01025 Boehringer Ingelheim Investigational Site
🇺🇸Valhalla, New York, United States
1160.53.55001 Boehringer Ingelheim Investigational Site
🇧🇷Cerqueira César - Sao Paulo, Brazil
1160.53.54003 Boehringer Ingelheim Investigational Site
🇦🇷Capital Federal, Argentina
1160.53.55002 Boehringer Ingelheim Investigational Site
🇧🇷Cerqueira César - São Paulo, Brazil
1160.53.01056 Boehringer Ingelheim Investigational Site
🇺🇸Hartford, Connecticut, United States
1160.53.01030 Boehringer Ingelheim Investigational Site
🇺🇸Grand Forks, North Dakota, United States
1160.53.42012 Boehringer Ingelheim Investigational Site
🇨🇿Liberec, Czech Republic
1160.53.55011 Boehringer Ingelheim Investigational Site
🇧🇷Goiânia -, Brazil
1160.53.01029 Boehringer Ingelheim Investigational Site
🇺🇸Pontiac, Michigan, United States
1160.53.01017 Boehringer Ingelheim Investigational Site
🇺🇸Richmond, Virginia, United States
1160.53.54005 Boehringer Ingelheim Investigational Site
🇦🇷Capital Federal, Argentina
1160.53.55010 Boehringer Ingelheim Investigational Site
🇧🇷Brasília, Brazil
1160.53.43001 Boehringer Ingelheim Investigational Site
🇦🇹Graz, Austria
1160.53.32001 Boehringer Ingelheim Investigational Site
🇧🇪Bruxelles, Belgium
1160.53.55014 Boehringer Ingelheim Investigational Site
🇧🇷Cristo Rei - Curitiba, Brazil
1160.53.55017 Boehringer Ingelheim Investigational Site
🇧🇷Paraná -, Brazil
1160.53.61006 The Avenue Cardiovascular Centre
🇦🇺Windsor, Victoria, Australia
1160.53.54017 Boehringer Ingelheim Investigational Site
🇦🇷Adrogué, Argentina
1160.53.55007 Boehringer Ingelheim Investigational Site
🇧🇷Campinas, Brazil
1160.53.32003 Boehringer Ingelheim Investigational Site
🇧🇪Brussel, Belgium
1160.53.02003 Boehringer Ingelheim Investigational Site
🇨🇦Sainte-Foy, Quebec, Canada
1160.53.54010 Boehringer Ingelheim Investigational Site
🇦🇷Capital Federal, Argentina
1160.53.55005 Boehringer Ingelheim Investigational Site
🇧🇷São José do Rio Preto, Brazil
1160.53.02021 Boehringer Ingelheim Investigational Site
🇨🇦Victoria, British Columbia, Canada
1160.53.02019 Boehringer Ingelheim Investigational Site
🇨🇦Toronto, Ontario, Canada
1160.53.36006 Boehringer Ingelheim Investigational Site
🇭🇺Budapest, Hungary
1160.53.45006 Boehringer Ingelheim Investigational Site
🇩🇰Slagelse, Denmark
1160.53.3310B Boehringer Ingelheim Investigational Site
🇫🇷Montpellier Cedex 5, France
1160.53.3310C Boehringer Ingelheim Investigational Site
🇫🇷Montpellier Cedex 5, France
1160.53.49017 Boehringer Ingelheim Investigational Site
🇩🇪Dresden, Germany
1160.53.02008 Boehringer Ingelheim Investigational Site
🇨🇦Montreal, Quebec, Canada
1160.53.3303D Boehringer Ingelheim Investigational Site
🇫🇷St Etienne Cedex 2, France
1160.53.3303E Boehringer Ingelheim Investigational Site
🇫🇷St Etienne Cedex 2, France
1160.53.3302A Boehringer Ingelheim Investigational Site
🇫🇷Lorient, France
1160.53.3301D Boehringer Ingelheim Investigational Site
🇫🇷Brest Cedex, France
1160.53.3311D Boehringer Ingelheim Investigational Site
🇫🇷Toulon Naval, France
1160.53.30006 Boehringer Ingelheim Investigational Site
🇬🇷Athens, Greece
1160.53.45002 Boehringer Ingelheim Investigational Site
🇩🇰Kolding, Denmark
1160.53.49018 Boehringer Ingelheim Investigational Site
🇩🇪Dresden, Germany
1160.53.36001 Boehringer Ingelheim Investigational Site
🇭🇺Budapest, Hungary
1160.53.3301A Boehringer Ingelheim Investigational Site
🇫🇷Brest Cedex, France
1160.53.3301I Boehringer Ingelheim Investigational Site
🇫🇷Brest Cedex, France
1160.53.02014 Boehringer Ingelheim Investigational Site
🇨🇦Montreal, Quebec, Canada
1160.53.3311A Boehringer Ingelheim Investigational Site
🇫🇷Toulon Naval, France
1160.53.3303C Boehringer Ingelheim Investigational Site
🇫🇷St Etienne Cedex 2, France
1160.53.3310A Boehringer Ingelheim Investigational Site
🇫🇷Montpellier Cedex 5, France
1160.53.36011 Boehringer Ingelheim Investigational Site
🇭🇺Szombathely, Hungary
1160.53.02001 Boehringer Ingelheim Investigational Site
🇨🇦Halifax, Nova Scotia, Canada
1160.53.42011 Boehringer Ingelheim Investigational Site
🇨🇿Hranice, Czech Republic
1160.53.42015 Boehringer Ingelheim Investigational Site
🇨🇿Novy Jicin, Czech Republic
1160.53.30005 Boehringer Ingelheim Investigational Site
🇬🇷Athens, Greece
1160.53.3308A Boehringer Ingelheim Investigational Site
🇫🇷Vandoeuvre les Nancy, France
1160.53.49003 Boehringer Ingelheim Investigational Site
🇩🇪Köln, Germany
1160.53.97211 Boehringer Ingelheim Investigational Site
🇮🇱Haifa, Israel
1160.53.36002 Boehringer Ingelheim Investigational Site
🇭🇺Debrecen, Hungary
1160.53.36004 Boehringer Ingelheim Investigational Site
🇭🇺Miskolc, Hungary
1160.53.02015 Boehringer Ingelheim Investigational Site
🇨🇦Ottawa, Ontario, Canada
1160.53.3301E Boehringer Ingelheim Investigational Site
🇫🇷Brest Cedex, France
1160.53.36003 Boehringer Ingelheim Investigational Site
🇭🇺Pecs, Hungary
1160.53.3303B Boehringer Ingelheim Investigational Site
🇫🇷St Etienne Cedex 2, France
1160.53.49009 Boehringer Ingelheim Investigational Site
🇩🇪Püttlingen, Germany
1160.53.3301F Boehringer Ingelheim Investigational Site
🇫🇷Brest Cedex, France
1160.53.30001 Boehringer Ingelheim Investigational Site
🇬🇷Athens, Greece
1160.53.39002 Boehringer Ingelheim Investigational Site
🇮🇹Padova, Italy
1160.53.36010 Boehringer Ingelheim Investigational Site
🇭🇺Székesfehérvár, Hungary
1160.53.02020 Boehringer Ingelheim Investigational Site
🇨🇦Quebec, Canada
1160.53.97205 Boehringer Ingelheim Investigational Site
🇮🇱KfarSaba, Israel
1160.53.97206 Boehringer Ingelheim Investigational Site
🇮🇱Petah Tiqwa, Israel
1160.53.3301C Boehringer Ingelheim Investigational Site
🇫🇷Brest Cedex, France
1160.53.3311C Boehringer Ingelheim Investigational Site
🇫🇷Toulon Naval, France
1160.53.36013 Boehringer Ingelheim Investigational Site
🇭🇺Eger, Hungary
1160.53.42004 Boehringer Ingelheim Investigational Site
🇨🇿Praha 2, Czech Republic
1160.53.31010 Boehringer Ingelheim Investigational Site
🇳🇱's Hertogenbosch, Netherlands
1160.53.45008 Boehringer Ingelheim Investigational Site
🇩🇰Esbjerg, Denmark
1160.53.45009 Boehringer Ingelheim Investigational Site
🇩🇰Holbæk, Denmark
1160.53.45004 Boehringer Ingelheim Investigational Site
🇩🇰København NV, Denmark
1160.53.45007 Boehringer Ingelheim Investigational Site
🇩🇰København S, Denmark
1160.53.39003 Boehringer Ingelheim Investigational Site
🇮🇹Bologna, Italy
1160.53.3301H Boehringer Ingelheim Investigational Site
🇫🇷Brest Cedex, France
1160.53.49007 Boehringer Ingelheim Investigational Site
🇩🇪München, Germany
1160.53.3308B Boehringer Ingelheim Investigational Site
🇫🇷Nancy, France
1160.53.64001 Boehringer Ingelheim Investigational Site
🇳🇿Takapuna Auckland, New Zealand
1160.53.3311E Boehringer Ingelheim Investigational Site
🇫🇷Toulon Naval, France
1160.53.36012 Boehringer Ingelheim Investigational Site
🇭🇺Gyula, Hungary
1160.53.97207 Boehringer Ingelheim Investigational Site
🇮🇱Ashkelon, Israel
1160.53.3301B Boehringer Ingelheim Investigational Site
🇫🇷Brest Cedex, France
1160.53.49005 Boehringer Ingelheim Investigational Site
🇩🇪Mannheim, Germany
1160.53.91021 Boehringer Ingelheim Investigational Site
🇮🇳Karna, India
1160.53.07011 Boehringer Ingelheim Investigational Site
🇷🇺Chelyabinsk, Russian Federation
1160.53.39005 Boehringer Ingelheim Investigational Site
🇮🇹Vittorio Veneto (tv), Italy
1160.53.07007 Boehringer Ingelheim Investigational Site
🇷🇺Ekaterinburg, Russian Federation
1160.53.27009 Suite 404, Medical Centre
🇿🇦Pretoria, South Africa
1160.53.34009 Boehringer Ingelheim Investigational Site
🇪🇸Madrid, Spain
1160.53.07016 Boehringer Ingelheim Investigational Site
🇷🇺Krasnodar, Russian Federation
1160.53.31009 Boehringer Ingelheim Investigational Site
🇳🇱Rotterdam, Netherlands
1160.53.5270 Boehringer Ingelheim Investigational Site
🇲🇽Culiacan, Mexico
1160.53.5262 Boehringer Ingelheim Investigational Site
🇲🇽San Luis Potosí, Mexico
1160.53.39001 Boehringer Ingelheim Investigational Site
🇮🇹Perugia, Italy
1160.53.97210 Boehringer Ingelheim Investigational Site
🇮🇱Tel-Aviv, Israel
1160.53.97202 Boehringer Ingelheim Investigational Site
🇮🇱Afula, Israel
1160.53.27007 Boehringer Ingelheim Investigational Site
🇿🇦Centurion, South Africa
1160.53.97201 Boehringer Ingelheim Investigational Site
🇮🇱Zerifin, Israel
1160.53.27002 Boehringer Ingelheim Investigational Site
🇿🇦Johannesburg, South Africa
1160.53.07005 Boehringer Ingelheim Investigational Site
🇷🇺Yaroslavl, Russian Federation
1160.53.47005 Boehringer Ingelheim Investigational Site
🇳🇴Trondheim, Norway
1160.53.31013 Boehringer Ingelheim Investigational Site
🇳🇱Eindhoven, Netherlands
1160.53.39007 Boehringer Ingelheim Investigational Site
🇮🇹Vimercate, Italy
1160.53.07001 Boehringer Ingelheim Investigational Site
🇷🇺St. Petersburg, Russian Federation
1160.53.97204 Boehringer Ingelheim Investigational Site
🇮🇱Tel Hashomer, Israel
1160.53.07009 Boehringer Ingelheim Investigational Site
🇷🇺Rostov-na-Donu, Russian Federation
1160.53.34012 Boehringer Ingelheim Investigational Site
🇪🇸Badalona (Barcelona), Spain
1160.53.07014 Boehringer Ingelheim Investigational Site
🇷🇺Ufa, Russian Federation
1160.53.27001 Boehringer Ingelheim Investigational Site
🇿🇦Johannesburg, South Africa
1160.53.27004 Boehringer Ingelheim Investigational Site
🇿🇦Johannesburg, South Africa
1160.53.47004 Boehringer Ingelheim Investigational Site
🇳🇴Oslo, Norway
1160.53.31002 Boehringer Ingelheim Investigational Site
🇳🇱Nieuwegein, Netherlands
1160.53.46007 Boehringer Ingelheim Investigational Site
🇸🇪Stockholm, Sweden
1160.53.46008 Boehringer Ingelheim Investigational Site
🇸🇪Stockholm, Sweden
1160.53.07023 Boehringer Ingelheim Investigational Site
🇷🇺Rostov-na-Donu, Russian Federation
1160.53.34010 Boehringer Ingelheim Investigational Site
🇪🇸Madrid, Spain
1160.53.27003 Boehringer Ingelheim Investigational Site
🇿🇦Randburg, South Africa
1160.53.34007 Boehringer Ingelheim Investigational Site
🇪🇸Cartagena. Murcia, Spain
1160.53.34001 Boehringer Ingelheim Investigational Site
🇪🇸Barcelona, Spain
1160.53.34005 Boehringer Ingelheim Investigational Site
🇪🇸Torrelavega.Santander, Spain
1160.53.27008 Suite M5, Second Floor
🇿🇦Richards Bay, South Africa
1160.53.90006 Boehringer Ingelheim Investigational Site
🇹🇷Izmir, Turkey
1160.53.27006 Boehringer Ingelheim Investigational Site
🇿🇦Johannesburg, South Africa
1160.53.34003 Boehringer Ingelheim Investigational Site
🇪🇸Cuenca, Spain
1160.53.27005 Boehringer Ingelheim Investigational Site
🇿🇦Roodepoort, South Africa
1160.53.07020 Boehringer Ingelheim Investigational Site
🇷🇺Omsk, Russian Federation
1160.53.44009 Boehringer Ingelheim Investigational Site
🇬🇧London, United Kingdom
1160.53.07018 Boehringer Ingelheim Investigational Site
🇷🇺Pskov, Russian Federation
1160.53.34004 Boehringer Ingelheim Investigational Site
🇪🇸Santander, Spain
1160.53.46005 Boehringer Ingelheim Investigational Site
🇸🇪Sundsvall, Sweden
1160.53.34011 Boehringer Ingelheim Investigational Site
🇪🇸Valencia, Spain
1160.53.44004 Boehringer Ingelheim Investigational Site
🇬🇧London, United Kingdom
1160.53.46002 Boehringer Ingelheim Investigational Site
🇸🇪Göteborg, Sweden
1160.53.90001 Boehringer Ingelheim Investigational Site
🇹🇷Istanbul, Turkey
1160.53.90005 Boehringer Ingelheim Investigational Site
🇹🇷Ankara, Turkey
1160.53.38005 Boehringer Ingelheim Investigational Site
🇺🇦Vinnitsa, Ukraine
1160.53.90007 Boehringer Ingelheim Investigational Site
🇹🇷Istanbul, Turkey
1160.53.31001 Boehringer Ingelheim Investigational Site
🇳🇱Amersfoort, Netherlands
1160.53.31005 Boehringer Ingelheim Investigational Site
🇳🇱Maastricht, Netherlands
1160.53.42005 Boehringer Ingelheim Investigational Site
🇨🇿Ostrava-Vitkovice, Czech Republic
1160.53.91010 Boehringer Ingelheim Investigational Site
🇮🇳New Delhi, India
1160.53.5264 Boehringer Ingelheim Investigational Site
🇲🇽Chihuahua, Mexico
1160.53.47003 Boehringer Ingelheim Investigational Site
🇳🇴Rud, Norway
1160.53.35104 Boehringer Ingelheim Investigational Site
🇵🇹Almada, Portugal
1160.53.42104 Boehringer Ingelheim Investigational Site
🇸🇰Zilina, Slovakia
1160.53.42010 Boehringer Ingelheim Investigational Site
🇨🇿Usti nad Labem, Czech Republic
1160.53.02004 Boehringer Ingelheim Investigational Site
🇨🇦Saint Johns, New Brunswick, Canada
1160.53.42002 Boehringer Ingelheim Investigational Site
🇨🇿Hradec Kralove, Czech Republic
1160.53.42014 Boehringer Ingelheim Investigational Site
🇨🇿Tabor, Czech Republic
1160.53.42009 Boehringer Ingelheim Investigational Site
🇨🇿Jihlava, Czech Republic
1160.53.42016 Boehringer Ingelheim Investigational Site
🇨🇿Teplice, Czech Republic
1160.53.91011 Boehringer Ingelheim Investigational Site
🇮🇳Bangalore, India
1160.53.42001 Boehringer Ingelheim Investigational Site
🇨🇿Brno, Czech Republic
1160.53.42007 Boehringer Ingelheim Investigational Site
🇨🇿Zlin, Czech Republic
1160.53.91022 Boehringer Ingelheim Investigational Site
🇮🇳Kerala, India
1160.53.35101 Boehringer Ingelheim Investigational Site
🇵🇹Lisboa, Portugal
1160.53.42107 Boehringer Ingelheim Investigational Site
🇸🇰Banska Bystrica, Slovakia
1160.53.42106 Boehringer Ingelheim Investigational Site
🇸🇰Lucenec, Slovakia
1160.53.91004 Boehringer Ingelheim Investigational Site
🇮🇳Vadodara, India
1160.53.35102 Boehringer Ingelheim Investigational Site
🇵🇹Lisboa, Portugal
1160.53.91013 Boehringer Ingelheim Investigational Site
🇮🇳Indore, India
1160.53.91008 Boehringer Ingelheim Investigational Site
🇮🇳Pune, India
1160.53.47001 Boehringer Ingelheim Investigational Site
🇳🇴Oslo, Norway
1160.53.42103 Boehringer Ingelheim Investigational Site
🇸🇰Nove Zamky, Slovakia
1160.53.35105 Boehringer Ingelheim Investigational Site
🇵🇹Lisboa, Portugal
1160.53.32007 Boehringer Ingelheim Investigational Site
🇧🇪Edegem, Belgium
1160.53.32005 Boehringer Ingelheim Investigational Site
🇧🇪Leuven, Belgium
1160.53.32004 Boehringer Ingelheim Investigational Site
🇧🇪Liège, Belgium
1160.53.44008 Boehringer Ingelheim Investigational Site
🇬🇧Aberdeen, United Kingdom
1160.53.44011 Boehringer Ingelheim Investigational Site
🇬🇧London, United Kingdom
1160.53.44006 Boehringer Ingelheim Investigational Site
🇬🇧Newcastle upon Tyne, United Kingdom
1160.53.02009 Boehringer Ingelheim Investigational Site
🇨🇦Montreal, Quebec, Canada
1160.53.02017 Boehringer Ingelheim Investigational Site
🇨🇦Montreal, Quebec, Canada
1160.53.01023 Boehringer Ingelheim Investigational Site
🇺🇸Detroit, Michigan, United States
1160.53.01028 Boehringer Ingelheim Investigational Site
🇺🇸Portland, Oregon, United States
1160.53.07003 Boehringer Ingelheim Investigational Site
🇷🇺Moscow, Russian Federation
1160.53.07006 Boehringer Ingelheim Investigational Site
🇷🇺Yaroslavl, Russian Federation
1160.53.01008 Boehringer Ingelheim Investigational Site
🇺🇸Decatur, Georgia, United States
1160.53.01019 Boehringer Ingelheim Investigational Site
🇺🇸Augusta, Georgia, United States
1160.53.01036 Boehringer Ingelheim Investigational Site
🇺🇸Albuquerque, New Mexico, United States
1160.53.01055 Boehringer Ingelheim Investigational Site
🇺🇸Summerville, South Carolina, United States
1160.53.54006 Boehringer Ingelheim Investigational Site
🇦🇷Capital Federal, Argentina
1160.53.61001 Boehringer Ingelheim Investigational Site
🇦🇺Clayton, Victoria, Australia
1160.53.55012 Boehringer Ingelheim Investigational Site
🇧🇷Porto Alegre, Brazil
1160.53.02005 Boehringer Ingelheim Investigational Site
🇨🇦Hamilton, Ontario, Canada
1160.53.3311B Boehringer Ingelheim Investigational Site
🇫🇷Toulon Naval, France
1160.53.3303A Boehringer Ingelheim Investigational Site
🇫🇷St Priest en Jarez, France
1160.53.91019 Boehringer Ingelheim Investigational Site
🇮🇳Chennai, India
1160.53.91020 Boehringer Ingelheim Investigational Site
🇮🇳Ludhiana, India
1160.53.91007 Boehringer Ingelheim Investigational Site
🇮🇳Mysore, India
1160.53.91005 Boehringer Ingelheim Investigational Site
🇮🇳Pune, India
1160.53.97203 Boehringer Ingelheim Investigational Site
🇮🇱Holon, Israel
1160.53.39004 Boehringer Ingelheim Investigational Site
🇮🇹Reggio Emilia, Italy
1160.53.31006 Boehringer Ingelheim Investigational Site
🇳🇱Amsterdam, Netherlands
1160.53.64003 Boehringer Ingelheim Investigational Site
🇳🇿Auckland, New Zealand
1160.53.31004 Boehringer Ingelheim Investigational Site
🇳🇱Rotterdam, Netherlands
1160.53.64004 Boehringer Ingelheim Investigational Site
🇳🇿Christchurch, New Zealand
1160.53.64002 Boehringer Ingelheim Investigational Site
🇳🇿Otahuhu Auckland, New Zealand
1160.53.35109 Boehringer Ingelheim Investigational Site
🇵🇹Coimbra, Portugal
1160.53.07021 Boehringer Ingelheim Investigational Site
🇷🇺Chelyabinsk, Russian Federation
1160.53.07004 Boehringer Ingelheim Investigational Site
🇷🇺Kursk, Russian Federation
1160.53.07010 Boehringer Ingelheim Investigational Site
🇷🇺Novosibirsk, Russian Federation
1160.53.07025 Boehringer Ingelheim Investigational Site
🇷🇺Rostov-na-Donu, Russian Federation
1160.53.07024 Boehringer Ingelheim Investigational Site
🇷🇺Rostov-na-Donu, Russian Federation
1160.53.34002 Boehringer Ingelheim Investigational Site
🇪🇸Barcelona, Spain
1160.53.46006 Boehringer Ingelheim Investigational Site
🇸🇪Jönköping, Sweden
1160.53.46001 Boehringer Ingelheim Investigational Site
🇸🇪Stockholm, Sweden
1160.53.90003 Boehringer Ingelheim Investigational Site
🇹🇷Ankara, Turkey
1160.53.90004 Boehringer Ingelheim Investigational Site
🇹🇷Ankara, Turkey
1160.53.46003 Boehringer Ingelheim Investigational Site
🇸🇪Uppsala, Sweden
1160.53.90002 Boehringer Ingelheim Investigational Site
🇹🇷Istanbul, Turkey
1160.53.38006 Boehringer Ingelheim Investigational Site
🇺🇦Kiev, Ukraine
1160.53.38003 Boehringer Ingelheim Investigational Site
🇺🇦Zaporozhye, Ukraine
1160.53.44005 Boehringer Ingelheim Investigational Site
🇬🇧Headington, Oxford, United Kingdom
1160.53.44012 Boehringer Ingelheim Investigational Site
🇬🇧Sheffield, United Kingdom
1160.53.02006 Boehringer Ingelheim Investigational Site
🇨🇦Edmonton, Alberta, Canada
1160.53.91015 Boehringer Ingelheim Investigational Site
🇮🇳Nagpur, India
1160.53.42102 Boehringer Ingelheim Investigational Site
🇸🇰Nitra, Slovakia
1160.53.61002 Boehringer Ingelheim Investigational Site
🇦🇺Woolloongabba, Queensland, Australia
1160.53.61003 Boehringer Ingelheim Investigational Site
🇦🇺Box Hill, Victoria, Australia
1160.53.01052 Boehringer Ingelheim Investigational Site
🇺🇸Altoona, Pennsylvania, United States
1160.53.02002 Boehringer Ingelheim Investigational Site
🇨🇦Hamilton, Ontario, Canada
1160.53.02022 Boehringer Ingelheim Investigational Site
🇨🇦Hamilton, Ontario, Canada
1160.53.61004 Boehringer Ingelheim Investigational Site
🇦🇺Bedford Park, South Australia, Australia
1160.53.61005 Boehringer Ingelheim Investigational Site
🇦🇺Perth, Western Australia, Australia
1160.53.02013 Boehringer Ingelheim Investigational Site
🇨🇦Edmonton, Alberta, Canada
1160.53.02010 Boehringer Ingelheim Investigational Site
🇨🇦Hamilton, Ontario, Canada
1160.53.02011 Boehringer Ingelheim Investigational Site
🇨🇦London, Ontario, Canada